The German Competition Regulator (Bundeskartellamt) has approved the acquisition of Cardior Pharmaceuticals GmbH (Cardior) by Novo Nordisk A/S (Novo Nordisk). Cardior is a biotech company, with operations in the development of active pharmaceutical ingredients for the medicines used for cardiac insufficiency or heart failure. On the other hand, Novo Nordisk is an international pharmaceutical company specializing in the development of treatment for diabetes & obesity. According to Bundeskartellamt, the proposed acquisition does not create any significant antitrust concerns as Cardior products works in a different way & is catrered towards a different set of consumers as compared to Novo Nordisk.
